BIO and the Delaware BioScience Association call upon Governor Markell to sign critical legislation to create pathway for the substitution of interchangeable biologic medicines. Senate Substitute 1 for Senate Bill 118 seeks to properly preserve patient access to accurate prescription information, maintains incentives for innovation, and promotes competitive market for biologic therapies. BIO will continue to advocate for full transparency in the substitution process.
This story is related to the following:Trade Associations